BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (BCRX) has announced the granting of restricted stock units (RSUs) to seven newly-hired employees. The compensation committee approved RSUs covering 65,900 shares of BioCryst common stock, granted on March 3, 2025. These inducement grants, issued under Nasdaq Listing Rule 5635(c)(4), will vest over four equal annual installments starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with the company. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and respective RSU agreements.
BioCryst Pharmaceuticals (BCRX) ha annunciato l'assegnazione di unità azionarie vincolate (RSU) a sette nuovi assunti. Il comitato per la compensazione ha approvato RSU che coprono 65.900 azioni ordinarie di BioCryst, concesse il 3 marzo 2025. Queste concessioni di indennizzo, emesse ai sensi della Regola di Quotazione Nasdaq 5635(c)(4), si matureranno in quattro rate annuali uguali a partire dal primo anniversario della data di concessione. La maturazione è subordinata al mantenimento dell'impiego presso l'azienda. Le RSU sono regolate dal Piano di Incentivazione Azionaria di BioCryst e dai rispettivi accordi RSU.
BioCryst Pharmaceuticals (BCRX) ha anunciado la concesión de unidades de acciones restringidas (RSUs) a siete empleados recién contratados. El comité de compensación aprobó RSUs que cubren 65,900 acciones ordinarias de BioCryst, otorgadas el 3 de marzo de 2025. Estas concesiones de incentivo, emitidas bajo la Regla de Cotización de Nasdaq 5635(c)(4), se consolidarán en cuatro cuotas anuales iguales a partir del primer aniversario de la fecha de concesión. La consolidación está sujeta a la continuación del empleo con la empresa. Las RSUs están reguladas por el Plan de Incentivo de Capital de Inducción de BioCryst y los respectivos acuerdos de RSU.
BioCryst Pharmaceuticals (BCRX)는 새로 채용된 직원 7명에게 제한 주식 단위(RSU)를 부여한다고 발표했습니다. 보상 위원회는 2025년 3월 3일에 부여된 BioCryst 보통주 65,900주를 포함하는 RSU를 승인했습니다. 이 유인 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 발행되며, 부여일로부터 1년 기념일에 시작하여 4개의 동등한 연간 할부로 분할됩니다. 이 취득은 회사와의 계속적인 고용에 따라 달라집니다. RSU는 BioCryst의 유인 주식 인센티브 계획 및 해당 RSU 계약에 의해 규제됩니다.
BioCryst Pharmaceuticals (BCRX) a annoncé l'octroi d'unités d'actions restreintes (RSU) à sept nouveaux employés. Le comité de rémunération a approuvé des RSU couvrant 65 900 actions ordinaires de BioCryst, accordées le 3 mars 2025. Ces octrois incitatifs, émis en vertu de la règle de cotation Nasdaq 5635(c)(4), seront acquis en quatre versements annuels égaux à partir du premier anniversaire de la date d'octroi. L'acquisition est conditionnée à la poursuite de l'emploi au sein de l'entreprise. Les RSU sont régies par le Plan d'Incitation en Actions de BioCryst et les accords RSU respectifs.
BioCryst Pharmaceuticals (BCRX) hat die Gewährung von Restricted Stock Units (RSUs) an sieben neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte RSUs für 65.900 Aktien von BioCryst, die am 3. März 2025 gewährt wurden. Diese Anreizgewährungen, die gemäß der Nasdaq-Listing-Regel 5635(c)(4) ausgegeben werden, werden in vier gleichen jährlichen Raten ab dem einjährigen Jubiläum des Gewährungsdatums fällig. Die Vesting ist abhängig von der fortgesetzten Beschäftigung im Unternehmen. Die RSUs unterliegen dem Anreiz-Eigenkapital-Plan von BioCryst und den jeweiligen RSU-Vereinbarungen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
How many RSUs did BioCryst (BCRX) grant to new employees in March 2025?
What is the vesting schedule for BioCryst's March 2025 RSU grants?
Under which Nasdaq rule were BioCryst's March 2025 RSUs granted?
What conditions apply to BioCryst's March 2025 RSU grants?
